Addex Therapeutics Shares Outstanding History (ADXN)
Addex Therapeutics reported 128.3M shares outstanding at the end of fiscal 2024.
View full Addex Therapeutics company overviewAddex Therapeutics annual shares outstanding history
| Fiscal year | Period ended | Shares outstanding | Change | Growth |
|---|---|---|---|---|
| 2024 | 2024-12-31 | 128.3M | 3.1M | +2.47% |
| 2023 | 2023-12-31 | 125.2M | 48.1M | +62.31% |
| 2022 | 2022-12-31 | 77.1M | 39.2M | +103.53% |
| 2021 | 2021-12-31 | 37.9M | 10.8M | +39.75% |
| 2020 | 2020-12-31 | 27.1M | 513,626 | +1.93% |
| 2019 | 2019-12-31 | 26.6M | 199,593 | +0.76% |
| 2018 | 2018-12-31 | 26.4M | 13.0M | +96.76% |
| 2017 | 2017-12-31 | 13.4M | — | — |
Addex Therapeutics quarterly shares outstanding
| Fiscal quarter | Period ended | Shares outstanding | Change | YoY change |
|---|---|---|---|---|
| Q2 2025 | 2025-06-30 | 141.2M | 64.1M | +83.05% |
| Q4 2024 | 2024-12-31 | 128.3M | 79.1M | +160.57% |
| Q4 2023 | 2023-12-31 | 125.2M | 87.3M | +230.54% |
| Q2 2023 | 2023-06-30 | 92.3M | 54.4M | +143.67% |
| Q4 2022 | 2022-12-31 | 77.1M | 50.0M | +184.43% |
| Q2 2022 · Jul 22 | 2022-07-22 | 49.2M | 22.6M | +85.06% |
| Q2 2022 · Jun 30 | 2022-06-30 | 37.9M | 11.5M | +43.44% |
| Q4 2021 | 2021-12-31 | 37.9M | 24.5M | +182.40% |
| Q4 2020 | 2020-12-31 | 27.1M | — | — |
| Q4 2019 | 2019-12-31 | 26.6M | — | — |
| Q4 2018 | 2018-12-31 | 26.4M | — | — |
| Q4 2017 | 2017-12-31 | 13.4M | — | — |
Addex Therapeutics shares outstanding trends
Over the last five reported fiscal years, Addex Therapeutics's shares outstanding moved from 26.6M to 128.3M, a change of 101.7M. The latest reported quarter, Q2 2025, shows 141.2M.
What shares outstanding means
Shares outstanding is the number of common shares held by investors at a reporting-period end. The count can change because of stock issuance, repurchases, conversions, acquisitions, or stock splits.
SEC-reported period-end shares
TickerStat displays period-end common shares from SEC filings and adjusts older values to the current share basis when SEC-reported stock-split conversion ratios are available. Values remain as reported when no split ratio is available. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Addex Therapeutics filings at SEC.gov ↗